CC-90005

oral, selective PKC_ kinase inhibitor

Ph. I candidate for Psoriasis

from screen of internal library and SBDD

Journal of Medicinal Chemistry

Celgene/BMS, San Diego, CA, USA

The Celgene/BMS PKCθ kinase inhibitor, CC-90005, highlighted by Julien Lefranc, is a clinical candidate in Ph. I for psoriasis, with some dosing being conducted in healthy volunteers. The safety profile is…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks